Pear Therapeutics Stock

peartherapeutics.comHealthcareFounded: 2013Funding to Date: $139MM

Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.

Register for Details

For more details on financing and valuation for Pear Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Pear Therapeutics.

Register Today

Team

Management Team

Alex Waldron
Chief Commercial Officer
Stephen Smith JD
Co-Founder & Executive Vice President of Corporate Development
Walter Greenleaf Ph.D
Chief Science Advisor
Christopher Guiffre JD
Chief Operating Officer & Chief Financial Officer
Yuri Maricich MD
Chief Medical Officer & Head of Clinical Development
Jeffrey Lieberman
Advisor
Corey McCann Ph.D
Co-Founder, President, Chief Executive Officer & Board Member
Jeremy Gilbert
Chief Product Officer
Beth Rogozinski
Chief Content Advisor

Board Members

Andrew Schwab
5AM Ventures
John Harris
JAZZ Venture Partners
Zack Lynch
JAZZ Venture Partners
Corey McCann Ph.D
Jeremy Sohn
Timothy Petersen
Arboretum Ventures
Delaine Cheong
Temasek Holdings
Jamil Beg
5AM Ventures
Thomas Shehab MD
Arboretum Ventures
Hu Hongjie
Temasek Holdings

Other companies like Pear Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$809.52MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$400.53MM
Sector
 
 
Sector
Last Round Est. Valuation
$1.53B
Sector
Last Round Est. Valuation
$396.01MM

News

The latest funding was led by Temasek, with participation from Novartis, 5AM Ventures, Arboretum Ventures, Jazz Partners, The Bridge Builders Collaborative and EDBI.
Updated on: Jun 8, 2023